Key Highlights
- Despite a currently muted equipment market, this part of Danaher Corporation’s (NYSE:DHR) business is growing at a high single-digit rate.
- Goldman Sachs expects overhangs hurting equipment demand are starting to ease and the pharmaceutical industry now has a clearer view on funding.
- Goldman Sachs and KeyBanc are Bullish on Danaher (DHR) Goldman Sachs also sees a shift towards Contract Development and Manufacturing Organization (CDMO) outsourcing to address onshoring.
- This could boost bioprocessing equipment orders in the near term.
- The research firm expects Danaher Corporation’s (NYSE:DHR) 2026 Biotechnology organic growth at 9.2%, which is higher than the consensus of 6.1%.
